HotSpot Therapeutics
Edit info- Founded: 2017
- Location: Boston, MA
- Employee range: 11 - 50
- Clinical stage: Clin1/Clin2
- Therapy area: Advanced solid tumors
- Drug types: IMM, ONC, RHU, MUS
- Lead product: HST-1011
- Funding: $100M C Nov 2021; $65M B May 2020; $45M A Jul 2018
hotspotthera.com linkedin.com job board
Business:
Small Molecules designed for Distinct Protein Domains
Drug notes:
Undisclosed RD autoimmune diseases; Undisclosed RD oncology
About:
HotSpot Therapeutics is pioneering a new approach to allosteric drug discovery. Many proteins have on/off switches called “natural hotspots” that are critical to a protein’s endogenous function. HotSpot is targeting these “natural hotspots” on proteins that are decisive in the control of cellular pathways and linked to various diseases. To achieve this, HotSpot is using their technology platform, Smart AllosteryTM, which is designed to systematically identify and drug natural hotspots across the proteome, including protein classes largely considered undruggable. HotSpot’s initial focus is on treating cancer and autoimmune diseases with their lead candidate, HST-1011, in development for CBL-B solid tumors.
Jobs:
News:
HotSpot Therapeutics to Present Initial First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024 - PR Newswire
googlenews
Jul 17, 2024
Science/business updates
external-link
HotSpot Therapeutics, Inc. - Massachusetts Biotechnology Council
googlenews
Nov 24, 2020
Funding-related
external-link
Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of …
crunchbase
Jul 12, 2023
Science/business updates
external-link
AbbVie offers up to $335M for connection with HotSpot's preclinical small-molecule program - Fierce Biotech
googlenews
Dec 6, 2022
Funding-related
external-link
HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer
crunchbase
Jul 25, 2022
New hires
external-link
Hotspot Therapeutics describes new MALT1 inhibitors for cancer
crunchbase
Mar 16, 2024
Science/business updates
external-link
Top 570+ startups in Cheminformatics for Drug Discovery in Nov, 2024 - Tracxn
googlenews
Nov 25, 2024
Science/business updates
external-link
The HotSpot team gathered for a potluck to enjoy foods ranging from smoked turkey to eggplant lasagna to sesame balls. What a treat to experience such a range of cooking and to come together ahead of
linkedin
Nov 23, 2024
New hires
external-link
Nimbus veterans launch allosteric drugmaker HotSpot ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
We’re looking forward to our presentation tomorrow at ESMO, where we’ll be presenting Phase 1 clinical data for HST-1011, our novel CBL-B inhibitor. Check out our latest release to learn more! https:/
linkedin
Sep 23, 2024
Science/business updates
external-link
Solid forms of a triazine derivative as cbl-b modulator
crunchbase
Jul 12, 2023
Science/business updates
external-link
This weekend, we will be presenting additional biomarker data from the Phase 1 study of HST-1011, our novel CBL-B inhibitor, at #SITC24. Check out our press release to learn more and stop by the poste
linkedin
Nov 23, 2024
Science/business updates
external-link
HotSpot Therapeutics Achieves First-In-Human Dosing with HST-1011, An Investigational Oral Small Molecule Allosteric Inhibitor of CBL-B - BioSpace
googlenews
Apr 11, 2023
Science/business updates
external-link
SR One fuels HotSpot's $65M B round to fund allosteric R&D
crunchbase
May 21, 2020
Funding-related
external-link
HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting - PR Newswire
googlenews
Nov 3, 2023
Science/business updates
external-link
HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer - PR Newswire
googlenews
Jul 25, 2022
New hires
external-link
The HotSpot team gathered in Boston for a stimulating week of conversation and collaboration, the highlight of which was a team-wide painting activity of the city’s skyline. The creativity really shin
linkedin
Jun 23, 2024
New hires
external-link
Hotspot Therapeutics describes new MK2 inhibitors
crunchbase
Mar 21, 2024
Science/business updates
external-link
We’re thrilled to welcome Alison O’Neill, M.D., who is joining HotSpot as Chief Medical Officer. Dr. O’Neill brings extensive clinical development experience, and she will be pivotal in advancing our
linkedin
Sep 23, 2024
New hires
external-link
HotSpot Therapeutics Appoints Alison O'Neill, M.D., as Chief Medical Officer
crunchbase
Sep 19, 2024
New hires
external-link
HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic - PR Newswire
googlenews
Nov 29, 2021
Funding-related
external-link
HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at ...
crunchbase
May 29, 2024
Science/business updates
external-link
Cancer-Targeting Biotech Startup HotSpot Therapeutics Raises $100M
crunchbase
Nov 29, 2021
Funding-related
external-link
All posts
web
Dec 23, 2024
No category can be assigned as the title "All posts" does not contain any specific information.
external-link
Join us in Barcelona at this year’s ESMO Congress 2024 for a Proffered Paper oral presentation featuring initial data from our first-in-human Phase 1 clinical trial of HST-1011, our novel, selective C
linkedin
Jul 23, 2024
Science/business updates
external-link
HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022 - PR Newswire
googlenews
Mar 8, 2022
Science/business updates
external-link
HotSpot Therapeutics snags $100M series C to bring ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
HotSpot Therapeutics debuts with $45 million to pursue allosteric inhibitors - Chemical & Engineering News
googlenews
Jul 17, 2018
Funding-related
external-link
Are we seeing glimmers of hope with the next wave of I-O therapies? Check out our recent blog post, which features some reflections on data recently presented at ESMO, including from our Phase 1 study
linkedin
Oct 23, 2024
Science/business updates
external-link
HotSpot Therapeutics Presents Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting - PR Newswire
googlenews
Nov 7, 2024
Science/business updates
external-link
Beyond COVID: Biotech And Health Care Trends To Watch In 2022
crunchbase
Jan 4, 2022
Science/business updates
external-link
HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic
crunchbase
Nov 29, 2021
Funding-related
external-link
Pfizer, Astellas win priority review for Xtandi sNDA; Hemispherx changes its name
crunchbase
Aug 23, 2019
Science/business updates
external-link
SR One fuels HotSpot's $65M B round to fund allosteric R&D - Fierce Biotech
googlenews
May 21, 2020
Funding-related
external-link
Pyridinylsulfonamide compounds and their use in therapy
crunchbase
Aug 25, 2023
Science/business updates
external-link
Hotspot Therapeutics patents CBL-B inhibitors - BioWorld Online
googlenews
Apr 30, 2024
Science/business updates
external-link
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors - PR Newswire
googlenews
Jul 19, 2022
New hires
external-link
HotSpot Therapeutics Expands Board of Directors and Management Team - PR Newswire
googlenews
Oct 30, 2018
New hires
external-link
Hotspot Therapeutics describes new MK2 inhibitors - BioWorld Online
googlenews
Mar 21, 2024
Science/business updates
external-link
HotSpot Therapeutics Raises $45 Million, Takes Nature’s Cue for Drug Development - The Wall Street Journal
googlenews
Jul 17, 2018
Funding-related
external-link
HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024 - PR Newswire
googlenews
Sep 12, 2024
Science/business updates
external-link
AbbVie doubles down on immunology, inks $40M collaboration with HotSpot Therapeutics - MM+M Online
googlenews
Dec 6, 2022
Funding-related
external-link
Pyrazolylsulfonamide compounds and their use in therapy
crunchbase
Aug 25, 2023
Science/business updates
external-link
UPDATED: HotSpot announces $65M Series B, as Nimbus pioneers look to keep up in a crowding field
crunchbase
May 21, 2020
Funding-related
external-link
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
crunchbase
May 21, 2020
Funding-related
external-link
HotSpot Therapeutics Presents Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting
crunchbase
Nov 7, 2024
Science/business updates
external-link
Today, we’re presenting preclinical data for our MALT1 CBM signalosome glue, highlighting the potential in NF-kB-driven solid tumors, at the 36th EORTC-NCI-AACR Symposium. If you’re on-site in Barcelo
linkedin
Oct 23, 2024
Science/business updates
external-link
HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
crunchbase
Jul 1, 2024
Science/business updates
external-link
HotSpot Therapeutics to Present Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium
crunchbase
Oct 9, 2024
Science/business updates
external-link
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors
crunchbase
Jul 19, 2022
New hires
external-link
Arcellx, recently reported the continued long-term responses
web
Dec 23, 2024
Science/business updates
external-link
HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma - PR Newswire
googlenews
Jun 20, 2024
Science/business updates
external-link
HotSpot Therapeutics to Present Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting - PR Newswire
googlenews
Oct 4, 2024
Science/business updates
external-link
AI ‘s Role in Drug Discovery: Separating the Hype from the Hope - HIT Consultant
googlenews
Nov 3, 2022
Science/business updates
external-link
HotSpot Therapeutics Presents Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium - PR Newswire
googlenews
Oct 23, 2024
Science/business updates
external-link
Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts
crunchbase
May 25, 2022
Science/business updates
external-link
Nimbus veterans launch allosteric drugmaker HotSpot Therapeutics with $45M series A - Fierce Biotech
googlenews
Jul 17, 2018
Funding-related
external-link
HotSpot doses first advanced solid tumour patient in Phase I/II study - Clinical Trials Arena
googlenews
Apr 12, 2023
Science/business updates
external-link
HotSpot Therapeutics Announces Acquisition of Macroceutics, Inc. - PR Newswire
googlenews
Aug 23, 2019
Funding-related
external-link
HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines - PR Newswire
googlenews
May 21, 2020
Funding-related
external-link
authorities who appear ready and willing to to engage with sponsors on this approach
web
Dec 23, 2024
Funding-related
external-link
Treatment of cell proliferation-associated conditions using a combination of a …
crunchbase
Jul 12, 2023
Science/business updates
external-link
Hotspot Therapeutics patents CBL-B inhibitors
crunchbase
May 4, 2024
Science/business updates
external-link
HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH ...
crunchbase
Dec 11, 2023
Science/business updates
external-link
HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B
crunchbase
Jan 3, 2023
Science/business updates
external-link
At today’s AACR Advances in Malignant Lymphoma Conference, we’re presenting preclinical data on HST-1021, our MALT1 scaffolding inhibitor. Swing by the poster today at 5:30 PM ET if you’re in Philadel
linkedin
Jun 23, 2024
Science/business updates
external-link
Antibody Therapeutics Market Worth $479.0 Billion ...
crunchbase
Dec 17, 2023
Science/business updates
external-link
HotSpot Therapeutics Appoints Alison O'Neill, M.D., as Chief Medical Officer - The Eastern Progress Online
googlenews
Dec 21, 2024
New hires
external-link
HotSpot Therapeutics to Present at the BMO Biopharma Spotlight Series
crunchbase
Feb 17, 2022
Science/business updates
external-link
HotSpot Therapeutics Announces Acquisition of Macroceutics, Inc.
crunchbase
Aug 23, 2019
Funding-related
external-link
Thanks to all who joined today’s presentation at ESMO! We appreciated the chance to share our data with the scientific community, and we’re looking forward to engaging in stimulating discussions and l
linkedin
Sep 23, 2024
Science/business updates
external-link
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com